Healthcare Industry News: radiosurgery
News Release - February 4, 2015
First TomoTherapy(R) System in Latin America Dedicated Solely to Breast Cancer Care Now Treating PatientsAdvanced Radiation Therapy System Ideally Suited for Efficient, Effective Treatment of Range of Breast Cancer Cases
SUNNYVALE, Calif., Feb. 4, 2015 -- (Healthcare Sales & Marketing Network) -- Accuray Incorporated (ARAY) announced today that the first TomoTherapy® System in Latin America dedicated solely to the treatment of breast cancer is now operational at FUCAM (Fundacion de Cancer de Mama) in Mexico City. More than 120 women have been treated with the innovative radiation therapy technology since the center began using it over two months ago. FUCAM's decision to install the TomoTherapy System reinforces growing medical community support for its use as a mainstream treatment to improve tumor control with reduced toxicities.
"We're honored that FUCAM selected the TomoTherapy System as their 'radiation therapy system of choice' to help them achieve their goal of offering breast cancer treatment to all women, regardless of their income," said Joshua H. Levine, president and chief executive officer of Accuray. "The system offers unique advantages in the treatment of breast cancer including the ability to deliver precise radiation dose to any tumor or tumor bed, during every treatment, while minimizing dose to organs at risk. This is especially important for women diagnosed with cancer in the left breast, where the tumor may be close to critical organs such as the heart."
The TomoTherapy System is the only radiation system specifically designed for image-guided intensity-modulated radiation therapy (IG-IMRT). Leveraging a CT scanner-based platform, TomoHelical™ Mode enables continuous delivery from 360 degrees around the patient with highly conformal and homogeneous dose to the tumor. A clinician can also choose to deliver treatment from specific fixed angles via TomoDirect™ Mode. With the TomoTherapy System, highly-sculpted dose distributions are achievable for the full range of breast cancer cases, from routine to complex.
"We (FUCAM) are a reference center for breast cancer patients, receiving about 1,000 new cases per year, so it was critical that we select a versatile and efficient radiation therapy system capable of delivering both hypofractionated and non-hypofractionated treatments to address a variety of patient needs," said Dra Judith Huerta Bahena, head of radiotherapy, Institute of Diseases of the Breast, FUCAM. "We considered TomoTherapy to be the ideal system for us based on recent studies demonstrating the system provides superior dose homogeneity with a lower dose to normal tissue, when compared to conventional treatments."
FUCAM is a civil partnership with a mission to provide diagnosis and treatment for breast cancer, particularly in the most vulnerable and marginalized in Mexico socioeconomic groups, and to promote education about early detection of breast cancer. It's the first non-profit institution established in Mexico and in Latin America with services, equipment, and highly specialized personnel fully-trained on the treatment of diseases of the breast. FUCAM developed one of the most important campaigns in Mexico to educate women on the importance of a screening mammography in the early detection of breast cancer.
About the TomoTherapy® System
The TomoTherapy System is capable of treating all standard radiation therapy indications, in addition to complex cases such as total marrow irradiation. Radiation oncologists have treated many types of cancers with the TomoTherapy System, including breast, prostate, lung, head & neck and pediatric. The system efficiently enables physicians to customize treatment plans for the entire range of radiation therapy patients and disease types. Its innovative design enables treatment plans to be delivered with integrated, daily CT image guidance, enhancing accuracy and delivering highly precise, intensity modulated radiation for optimal sparing of healthy tissue and critical structures.
Accuray Incorporated (ARAY) is a radiation oncology company that develops, manufactures and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit www.accuray.com.
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to the adoption and acceptance of the company's products, clinical experience, clinical applications, clinical results, patient outcomes and Accuray's leadership position in radiation oncology innovation and technologies. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to the risks detailed under the heading "Risk Factors" in the company's report on Form 10-K, filed on August 29, 2014, the company's report on Form 10-Q, filed on November 7, 2014, and the company's other filings with the SEC.
Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsPhase 3 Randomized Trial Data Shows SBRT has Similar Acute Safety Profile to Conventional Radiation Therapy in Patients with Localized Prostate Cancer
Accuray and China Isotope and Radiation Corporation Enter Joint Venture Contract to Manufacture and Sell Radiation Oncology Systems in China
Accuray CyberKnife(R) System Treatment Delivery Times Up to 50 Percent Faster With Software Upgrade